期刊文献+

卡瑞利珠单抗联合仑伐替尼治疗晚期肝癌的有效性及安全性分析

Analysis of the Efficacy and Security of Camrelizumab Combined with Lenvatinib in the Treatment of Advanced Liver Cancer
原文传递
导出
摘要 目的探讨卡瑞利珠单抗联合仑伐替尼治疗晚期肝癌患者的效果。方法回顾性分析2020年1月—2023年1月于我院接受治疗的86例晚期肝癌患者的临床资料。依据治疗方案的不同,将接受仑伐替尼治疗的43例患者纳入对照组,将接受卡瑞利珠单抗联合仑伐替尼治疗的43例患者纳入观察组。比较两组治疗有效性、生化指标水平与安全性。结果观察组疾病控制率为72.09%,高于对照组的48.84%,差异有统计学意义(P<0.05)。治疗3个疗程后,观察组甲胎蛋白(AFP)、异常凝血酶原(APT)水平均低于对照组,组间差异有统计学意义(P<0.05)。两组手足综合征、疲乏、皮疹、腹泻、食欲下降、胆红素升高、急性肾损伤、甲状腺功能减退、肝功能异常、血小板减少发生率比较,组间差异无统计学意义(P>0.05)。结论晚期肝癌患者经卡瑞利珠单抗联合仑伐替尼治疗效果显著,可有效改善AFP、APT水平,且具有一定安全性。 Objective To explore the efficacy of camrelizumab combined with lenvatinib in the treatment of advanced liver cancer patients.Methods A retrospective analysis was conducted on the clinical data of 86 patients with advanced liver cancer who received treatment in our hospital from January 2020 to January 2023.According to different treatment plans,the data of 43 patients receiving lenvatinib treatment were divided into a control group,and the data of 43 patients receiving camrelizumab combined with lenvatinib treatment were divided into an observation group.The therapeutic efficacy,biochemical indicators,and safety of the two groups were compared.Results The disease control rate of the observation group was 72.09%,higher than 48.84%of the control group,and the difference was statistically significant(P<0.05).After three courses of treatment,the levels of alpha-fetoprotein(AFP),abnormal prothrombin(APT)in the observation group were lower than those in the control group,and the differences between the groups were statistically significant(P<0.05).There was no statistically significant difference in the incidence of hand foot syndrome,fatigue,rash,diarrhea,decreased appetite,elevated bilirubin,acute kidney injury,hypothyroidism,liver dysfunction,and thrombocytopenia between the two groups(P>0.05).Conclusion The combination of camrelizumab and lenvatinib in the treatment of advanced liver cancer patients has a significant effect,can effectively improve AFP and APT levels,and has a certain security.
作者 梁劲波 彭荣 LIANG Jinbo;PENG Rong(Department of Oncology,Yicheng People's Hospital,Yicheng Hubei,441400,China)
出处 《反射疗法与康复医学》 2024年第7期157-159,163,共4页 Reflexology And Rehabilitation Medicine
关键词 晚期肝癌 卡瑞利珠单抗 仑伐替尼 安全性 Advanced liver cancer Camrelizumab Lenvatinib Security
  • 相关文献

参考文献10

二级参考文献129

  • 1王砚亮,宋威,卞益同,张小彪,李发中.CT量化碘油摄取预测原发性肝癌TACE术后肿瘤复发的临床价值[J].临床放射学杂志,2020,39(3):573-578. 被引量:23
  • 2陈建国,宋新明.中国肝癌发病水平的估算及分析[J].中国肿瘤,2005,14(1):28-31. 被引量:93
  • 3吴孟超.应重视小肝癌的诊断与治疗[J].中华医学杂志,2007,87(30):2089-2091. 被引量:11
  • 4丛文铭,董 辉,冼志红. 肝脏和肝内胆管系统肿瘤[M]//吴秉铨,刘彦仿. 免疫组织化学病理诊断. 2版. 北京:北京科学技术出版社, 2013:334-45.
  • 5KOH C, ZHAO X, SAMALA N, et al. AASLD clinical practice guidelines: a critical review of scientific evidence and evolving recommendations[J]. Hepatology, 2013, 58(6): 2142-2152.
  • 6WILLIAM H, RALPH H, TIMOTHY H, et al. Surgical patholo- gy dissection : an illustrated guide[ M ]. New York : Springer, 2003 : 7 -9.
  • 7中华医学会临床技术操作规范·病理学分册[M].北京:人民军医出版社,2004:27-41.
  • 8BASS BP, ENGEL KB, GREYTAK SR, et al. A review of pre- analytical factors affecting molecular, protein, and morpho- logical analysis of formalin -fixed, paraffin - embedded ( FF- PE) tissue., how well do you know your FFPE specimen? [J]. Arch Pathol Lab Med, 2014, 138(11 ) : 1520 -1530.
  • 9LU XY, XI T, LAU WY, et al. Hepatocellular carcinoma ex- pressing cholangiocyte phenotype is a novel subtype with highly aggressive behavior[J]. Ann Surg Oncol, 2011, 18 (8) : 2210 -2217.
  • 10CAI SW, YANG SZ, GAO J, et al. Prognostic significance of mast cell count following curative resection for pancreatic ductal adenocarcinoma[J]. Surgery, 2011, 149(4): 576 -584.

共引文献178

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部